Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

2.230 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.230
Bid (Size) 2.100 (2)
Ask (Size) 2.330 (15)
Prev. Close 2.230
Today's Range 2.230 - 2.230
52wk Range 2.180 - 6.050
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings For Allogene Therapeutics
Via Benzinga
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence. 
Via InvestorPlace

Performance

YTD
-38.40%
-38.40%
1 Month
-13.90%
-13.90%
3 Month
-49.66%
-49.66%
6 Month
-19.78%
-19.78%
1 Year
-53.64%
-53.64%

More News

Read More
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Recap: Allogene Therapeutics Q4 Earnings
Via Benzinga
Allogene Therapeutics Earnings Preview
Via Benzinga
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Via Benzinga
Topics ETFs
3 Meme Stocks to Sell and Replace With Meme Coins
Via InvestorPlace
Allogene Therapeutics Announces Q2 Investor Conference Participation
From Allogene Therapeutics, Inc.
Via GlobeNewswire
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.